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Abstract
Objective—To investigate the association between HIV, antiretroviral therapy (ART), and 
pregnancy-associated hypertension (PAH) in an HIV-endemic setting.
Methods—A retrospective cohort study was undertaken of pregnant women for whom 
information was recorded between February 2006 and December 2012 in the Zambia Electronic 
Perinatal Record System, which captures data from 25 facilities in Lusaka, Zambia. PAH was 
defined as eclampsia, pre-eclampsia, hypertension, or elevated blood pressure (>140/80 mm Hg) 
during delivery admission. Logistic regression estimated the odds of PAH among women by HIV 
serostatus, and by most recent CD4 T lymphocyte count and ART status among women with HIV 
infection.
Results—Among 249 771 women included in the analysis, 5354 (2.1%) had PAH. Compared 
with women without HIV infection, women with HIV infection not receiving ART had lower odds 
of PAH (adjusted odds ratio [AOR] 0.86, 95% confidence interval 0.78–0.95), whereas those with 
HIV infection who had initiated ART had higher odds of PAH (AOR 1.15, 95% CI 1.01–1.32). No 
association was found between PAH and timing of ART initiation or CD4 lymphocyte count.
Conclusion—In a large African urban cohort, women with untreated HIV infection had the 
lowest odds of PAH. Treatment with ART could increase PAH risk beyond that of women without 
HIV infection and those with untreated infection.
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1. Introduction
Increased access to antiretroviral therapy (ART) has substantially reduced the risk of 
mother-to-child transmission of HIV worldwide. Nevertheless, there are growing concerns 
about the effects of long-term use of ART on adverse fetal, infant, and maternal outcomes, 
including hypertensive disorders of pregnancy such as gestational hypertension and pre-
eclampsia [1–3]. The American College of Obstetricians and Gynecologists defines 
gestational hypertension as elevated blood pressure after 20 weeks of pregnancy in the 
absence of proteinuria or new signs of end-organ dysfunction [4]. Pre-eclampsia is defined 
as blood pressure elevation after 20 weeks of pregnancy with proteinuria or new signs of 
end-organ dysfunction [4].
Before the ART era, pregnant women with HIV infection were found to be at a decreased 
risk of pre-eclampsia compared with women without HIV infection [5,6]. However, with the 
increasing availability of ART, there has been a trend toward increased incidence of pre-
eclampsia among women with HIV infection. In a study of 11 European countries, pre-
eclampsia was the most common adverse outcome among pregnant women receiving ART 
[3]. A study in Spain [2] found that women living with HIV and receiving ART before 
pregnancy had a five-fold increase in the likelihood of pre-eclampsia compared with 
counterparts not receiving treatment or receiving fewer than three antiretroviral drugs (odds 
ratio [OR] 5.6, 95% confidence interval [CI] 1.7–18.1). However, the results have not been 
consistent; other studies have found no association [5,7–9] or a lower risk of pre-eclampsia 
among women receiving ART than among women without HIV infection [10,11]. The aim 
of the present study was to investigate the association between HIV status, ART, and 
development of pregnancy-associated hypertension (PAH) in a large cohort of women in 
Lusaka, Zambia.
2. Materials and methods
A retrospective cohort study was undertaken of pregnant women for whom information 
about prenatal care and delivery was recorded in the Zambia Electronic Perinatal Record 
System (ZEPRS) between February 1, 2006, and December 31, 2012. ZEPRS is an 
electronic medical record system that captures data on women receiving prenatal care and 
delivery services at 25 public health facilities, including the University Teaching Hospital 
(UTH), in Lusaka [12]. Use of these data was approved by the Biomedical Research Ethics 
Committee at the University of Zambia School of Medicine (Lusaka, Zambia) and by the 
Institutional Review Board of the University of North Carolina at Chapel Hill (Chapel Hill, 
NC, USA). ZEPRS was established for routine clinical care purposes and individual 
informed consent was not obtained directly from patients; however, all individual identifiers 
were removed before data analysis.
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Lusaka has a population of 2 million and is served by the 25 district public health sector 
facilities covered by ZEPRS. The rate of HIV infection among pregnant women attending 
these facilities is estimated to be 22% [12]. Zambian national guidelines for the prevention 
of mother-to-child transmission of HIV have evolved since 2001, when provider-initiated 
testing and counseling, and maternal and infant antiretroviral prophylaxis became the 
standard of care [13]. The guidelines now recommend that all pregnant women with HIV 
infection start lifelong ART irrespective of their CD4 count or clinical stage [14]. Changes in 
policy have resulted in a large, and growing, number of women in Lusaka receiving ART 
during pregnancy.
In the study setting, many delivery locations lacked the laboratory capacity to diagnose 
proteinuria or other abnormalities necessary to meet the diagnostic criteria for pre-eclampsia 
as defined in the American College of Obstetricians and Gynecologists guidelines [4]. 
Women were diagnosed empirically, on the basis of blood pressure and symptoms, including 
neurological symptoms and/or seizures. Women with hypertension were diagnosed at the 
time of labor and delivery admission according to an a priori definition of PAH: (1) 
eclampsia as defined by local practitioners, (2) pre-eclampsia as defined by local 
practitioners, (3) diagnosis of hypertension (yes/no), or (4) a recorded systolic blood 
pressure of or above 140 mm Hg or diastolic blood pressure of or above 90 mm Hg during 
labor and delivery admission. All four diagnoses were established using a “problem labor” 
form completed by clinical or research staff when a woman was identified as having a high-
risk pregnancy according to local practices. Women with chronic hypertension—i.e. a 
documented medical history of hypertension before pregnancy—were excluded from the 
analysis. Hypertension during prenatal care was defined as elevated blood pressure during 
any prenatal care visit; it was not included in the outcome definition because time of blood 
pressure reading was unknown.
HIV status and treatment were classified into three groups: (1) women without HIV 
infection; (2) women with HIV infection that was untreated, who initiated mother-to-child 
transmission prophylaxis or a non-suppressive regimen (i.e. peripartum nevirapine with or 
without prenatal zidovudine) during pregnancy and labor; and (3) women with HIV 
infection who had been receiving combination ART (i.e. ≥3 drugs) since before pregnancy 
or who initiated such a regimen during pregnancy. Timing of ART initiation was 
dichotomized as initiation during or before pregnancy. Length of pregnancy was based on 
the last menstrual period; routine obstetrical ultrasonography for confirmation of gestational 
age was not routinely available in the study setting.
Maternal and newborn characteristics were compared between women with and without 
PAH. Frequencies and percentages or medians with the interquartile range were reported and 
were compared using χ2 or Wilcoxon tests, as appropriate. A logistic regression model was 
used to estimate the OR for the association between HIV status and treatment, and PAH. 
Generalized estimating equations with an unstructured correlation structure were used to 
create 95% CIs that account for repeat deliveries over the study period. Potential 
confounders deemed clinically important and which were significantly associated with the 
outcome in univariable analysis at an alpha level of P<0.05 were included in the 
multivariable logistic regression model. Age was modeled using a quadratic term because 
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results from a likelihood ratio test indicated that a model with the quadratic term was a better 
fit to the data compared with a model with linear age (P<0.001). Two subanalyses were 
performed, including a model restricted to women with HIV infection and one restricted to 
women receiving ART, to further explore the association between CD4 lymphocyte count, 
timing of treatment initiation, and PAH. Another subgroup analysis was performed to 
explore how excluding blood pressure from the outcome definition affected the results 
because only one measurement was recorded and the other three diagnoses (eclampsia, pre-
eclampsia, and hypertension) were identified by local standards. All subanalyses were 
defined a priori. All analyses were conducted with SAS version 9.3 (SAS Institute, Cary, 
NC, USA).
3. Results
A prenatal care visit was recorded for 390 244 women during the study period. Final 
analyses included 249 771 women (Figure 1).
Among the 249 771 included women, 5354 (2.1%) met the criteria for PAH. Most (n=4671 
[87.2%]) met the criteria on the basis of blood pressure measurements; a smaller number of 
women had a diagnosis of pre-eclampsia (n=701 [13.1%]), hypertension (n=372 [6.9%]), or 
eclampsia (n=394 [7.4%]), although these categories are not mutually exclusive. Compared 
with women without PAH, those with the disorder had a significantly higher body mass 
index (BMI, calculated as weight in kilograms divided by the square of height in meters) and 
more frequently had a multiple pregnancy, hypertension during prenatal care, and a neonate 
weighing 1500–2500 g at birth (P<0.001 for all) (Table 1). They were also more frequently 
in the youngest or oldest age groups (P<0.001) (Table 1). The proportion of women without 
HIV infection was higher among those with PAH than among those without this disorder, 
and more women in the PAH group had HIV infection and were receiving ART (Table 1).
In the primary analysis, PAH was associated with parity, BMI, multiple pregnancy, and HIV 
status and treatment (Table 2). PAH was also associated with age (data not shown). In 
unadjusted models, women with HIV infection who were untreated or given prophylaxis had 
a lower likelihood of PAH than did women without HIV infection, whereas women with 
HIV infection given ART had similar odds to women without the infection (Table 2). In 
multivariable analysis, women receiving ART had significantly increased odds of PAH when 
compared with HIV-negative women (Table 2). Women with HIV infection not receiving 
ART still had decreased odds. In a subanalysis that excluded blood pressure measurements 
from the outcome, similar patterns were noted in the odds of PAH among women with an 
untreated HIV infection and women living with HIV and receiving ART when compared 
with those who did not have HIV infection (Table 2).
Among the women with HIV infection, PAH was associated with parity, BMI, multiple 
pregnancy, and ART (Table 3). PAH was also associated with age (data not shown). The 
odds of PAH among women receiving ART were 1.27-fold those of PAH in untreated 
women or those receiving prophylaxis only. Most recent CD4 count was not associated with 
PAH.
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Among the 12 813 women with HIV infection receiving ART for whom timing of initiation 
was known, 11 581 (90.4%) initiated treatment during pregnancy. PAH was associated with 
BMI and multiple pregnancy (Table 3). In multivariable analysis, women initiating treatment 
during pregnancy had similar odds of PAH to those initiating treatment before pregnancy 
(Table 3). Most recent CD4 count was not associated with PAH.
4. Discussion
The present results suggest that women with an untreated HIV infection had lower odds of 
PAH than did women without HIV infection. However, on initiation of ART, the risk of PAH 
for women with HIV infection could return to baseline levels or even increase. An 
association between timing of ART initiation and PAH was not observed. These findings are 
consistent with previous studies and indicate that women initiating ART during pregnancy 
could require increased surveillance and treatment for hypertensive disorders of pregnancy 
[2,5].
Diagnosing hypertensive disorders of pregnancy in the study settings is a challenge. During 
prenatal care, blood pressure measurements are not consistently recorded and the timing of 
these measurements is uncertain. Information on proteinuria is not available because not all 
delivery locations have diagnostic laboratory capacity. Therefore, blood pressure elevation 
could not be reliably diagnosed after 20 weeks of pregnancy as indicated in the current 
definition of gestational hypertension and pre-eclampsia [4].
The outcome metric of PAH was developed to reflect these challenges. PAH was defined as 
a diagnosis of elevated blood pressure identified on admission to labor and delivery. Because 
of the structure of ZEPRS, in which a “problem form” is created only for recognized 
complications, women diagnosed with PAH in the analysis cohort probably represent severe 
cases. The use of hypertension diagnosed during labor and delivery admission and not at any 
prenatal care visit would have also resulted in an underestimate of the prevalence of 
gestational hypertension in this population. However, the results remained consistent when 
blood pressure measurements were excluded from the outcome definition.
The present findings support a reduced risk of hypertension among pregnant women with 
HIV infection when compared with uninfected women [5,6,15] and a higher risk among 
women receiving ART compared with those receiving no treatment or fewer than three 
antiretroviral drugs [2,5]. However, the estimates for the association between ART and 
hypertension are modest compared with previous studies, which have demonstrated more 
than a five-fold increase among women receiving ART [2,5]. The lower estimates observed 
in the present study could be a result of an under-representation of pre-eclampsia without 
severe features or mild gestational hypertension in the study sample. As far as we are aware, 
this is the first study to report higher odds of hypertension among women with HIV 
infection receiving ART than among women without HIV infection. Previous studies 
comparing treated women with women without HIV infection have found no association 
[5,7–9] or a lower risk among women taking ART [10,11].
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Hypertension in pregnancy during ART use could be linked to immune reconstitution 
following HIV treatment [5]. A leading theory is that pre-eclampsia develops from an 
excessive generalized maternal inflammatory response during pregnancy [16]. Because 
women living with HIV have decreased CD4 T lymphocyte cell counts, their immune 
system might be less likely to have an immunological hyper-reactivity to the pregnancy, 
leading to a reduced incidence of pre-eclampsia. This reduced risk is restored back to pre-
infection levels among women receiving ART as a result of increasing CD4 T lymphocyte 
levels [5]. The present findings are compatible with this theory, although a relationship 
between PAH and either CD4 T lymphocyte count or timing of ART initiation was not 
observed, as might have been expected under this hypothesis. Thus, additional research is 
needed to further clarify these relationships. Specifically, studies focusing on African 
countries are urgently needed given that the number of pregnant women being treated for 
HIV infection in the region continues to increase, and that access to obstetric care and the 
ability to recognize and safely manage pre-eclampsia remain limited [17,18].
Estimates of the incidence of pre-eclampsia from South Africa, Egypt, Tanzania, Ethiopia, 
and Nigeria range from 1.8% to 16.7% [19]. Given the broader definition for PAH used in 
the present study, the 2.1% frequency obtained is much lower than would be expected. The 
definition of PAH used in the present study includes hypertensive disorders diagnosed only 
during labor and delivery admission, but not during any prenatal care visit. This would have 
resulted in an underestimation of PAH given the exclusion of women with either new-onset 
hypertension detected in prenatal care or superimposed pre-eclampsia. Additionally, women 
for whom the “problem labor” form used to diagnose PAH was not completed were defined 
as having a normal pregnancy; if these women indeed had undiagnosed PAH, this would 
have contributed to the low recorded incidence. Finally, data on proteinuria is not reliably 
captured in the ZEPRS database and it was not possible to distinguish gestational 
hypertension from the more precise definition of pre-eclampsia. However, these diagnostic 
challenges do reflect the reality of care in the study settings, where only women with severe 
cases of PAH might be identified. It is likely that women with more severe symptoms were 
identified and that the risk factors associated with PAH are similar to those found in previous 
studies [20].
Several additional limitations are noted. First, only one measure of blood pressure was 
recorded. However, a subanalysis removing systolic and diastolic blood pressure from the 
outcome definition showed similar results. Second, the most recent CD4 cell count was 
used, but it is recognized that changes with time could have been a more appropriate 
measure of immune reconstitution. Finally, no information related to viral load or 
antiretroviral drug adherence was available in ZEPRS. Thus, poor adherence to ART, for 
example, would have biased the results toward the null.
In summary, the present findings highlight the importance of monitoring and treating 
hypertensive disorders during pregnancy, particularly among women with HIV infection 
taking ART. However, given the lack of data to appropriately diagnose pre-eclampsia, 
studies that can more precisely identify pre-eclampsia in African settings are needed. 
Although the database is large and indicates that PAH could be an issue in this population, 
pre-eclampsia specifically can lead to serious complications during pregnancy and should be 
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better understood. Monitoring of hypertension during pregnancy is critical given recent 
policy changes in Sub-Saharan African countries—including Zambia—that will 
dramatically increase the number of women with HIV infection initiating ART.
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In Lusaka, Zambia, women with HIV infection receiving antiretroviral therapy have 
higher odds of pregnancy-associated hypertension than women without HIV infection or 
with untreated infection.
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Flow of patients through the study. Abbreviation: ZEPRS, Zambia Electronic Perinatal 
System.
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Table 1
Characteristics of participants by PAH status.a
Characteristic PAH P value
No (n=244 417) Yes (n=5354)
HIV status and treatmentb
 Negative 184 042 (78.0) 4115 (80.2) <0.001c
 Positive, untreated 5869 (2.5) 106 (2.1)
 Positive, given prophylaxis 31 154 (13.2) 545 (10.6)
 Positive, given antiretroviral therapy 14 996 (6.4) 362 (7.1)
Maternal age, y 25 (21–29) 25 (20–31) <0.001d
  <20 44 942 (18.4) 1069 (20.0) <0.001c
  20–24 76 596 (31.3) 1356 (25.3)
  25–34 104 148 (42.6) 2271 (42.4)
  ≥35 18 731 (7.7) 658 (12.3)
Parity 1 (0–2) 1 (0–2) <0.001c
Length of pregnancy at first prenatal care visit (according to last menstrual period), wke 22 (18–26) 21 (17–25) <0.001d
  <14 20 892 (8.6) 565 (10.6)
  14–24 131 018 (53.8) 3059 (57.2)
  ≥24 91 805 (37.7) 1725 (32.2)
Baseline body mass indexf 23.4 (21.4–26.0) 24.5 (22.1–28.0) <0.001d
  <18.5 5137 (3.1) 73 (2.0) <0.001c
  18.5–24 104 864 (64.3) 1897 (52.1)
  24–29 40 640 (24.9) 1068 (29.3)
  ≥30 12 571 (7.7) 602 (16.5)
Multiple pregnancy 3677 (1.5) 196 (3.7) <0.001c
Hypertension during prenatal careg
  No 209 314 (94.8) 3981 (78.6) <0.001c
  Yes 11 430 (5.2) 1087 (21.4)
Baseline hemoglobin, g/Lh 116 (107–126) 117 (109–126) <0.001d
  ≥100 104 311 (90.3) 2356 (91.9) 0.013c
  80–90 9878 (8.6) 188 (7.3)
  <80 1323 (1.1) 19 (0.7)
Baseline syphilis by rapid plasma reagini
  Non-reactive 164 710 (96.5) 3828 (97.0) <0.001c
  Reactive/no documentation of treatment 1838 (1.1) 30 (0.8)
  Reactive/documentation of treatment 4135 (2.4) 90 (2.3)
Neonate birth weight, gj 3000 (2700–3300) 3000 (2600–3300) <0.001d
  <1000 702 (0.3) 30 (0.6) <0.001c
  1000–1500 2275 (0.9) 141 (2.7)
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Characteristic PAH P value
No (n=244 417) Yes (n=5354)
  1500–2500 23 235 (9.6) 849 (16.2)
  >2500 215 456 (89.2) 4227 (80.6)
Most recent CD4 count (among women with HIV infection), cells/mm3 k 421 (286–579) 413 (278–568) 0.600d
  <200 4468 (11.9) 76 (11.2) 0.637c
  200–250 9159 (24.4) 179 (26.4)
  350–500 10 316 (27.5) 189 (27.8)
  ≥500 13 613 (36.2) 235 (34.6)
Abbreviation: PAH, pregnancy-induced hypertension
aValues are given as number (percentage) or median (interquartile range), unless indicated otherwise.
b




Data available for 243 715 women without PAH and 5349 with PAH.
fCalculated as weight in kilograms divided by the square of height in meters. Data available for 163 212 women without PAH and 3640 with PAH.
g
Data available for 220 744 women without PAH and 5068 with PAH.
h
Data available for 115 512 women without PAH and 2563 with PAH.
i
Data available for 170 683 women without PAH and 3948 with PAH.
j
Data available for 241 668 women without PAH and 5247 with PAH.
k
Data available for 37 556 women with HIV infection and without PAH and 679 with HIV infection and PAH.
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Table 2
Logistic regression of factors associated with pregnancy-associated hypertension.a,b
Factor Crude modelc Adjusted modeld Adjusted model excluding systolic and diastolic 
blood pressurese
HIV status and treatment
 Negative 1 1 1
 Positive, untreated or given prophylaxis only 0.78 (0.72–0.85) 0.86 (0.78–0.95) 0.75 (0.61–0.93)
 Positive, given antiretroviral therapy 1.07 (0.96–1.19) 1.15 (1.01–1.32) 1.05 (0.80–1.38)
Parity
 0 1 1 1
 ≥1 0.73 (0.69–0.77) 0.66 (0.62–0.71) 0.58 (0.50–0.66)
Multiple pregnancy
 No 1 1 1
 Yes 2.49 (2.15–2.88) 2.52 (2.11–3.01) 4.53 (3.45–5.94)
Baseline body mass index f
 <18.5 0.79 (0.62–0.99) 0.77 (0.61–0.97) 0.63 (0.37–1.07)
 18.5–24 1 1 1
 25–29 1.45 (1.35–1.57) 1.46 (1.35–1.58) 1.63 (1.40–1.91)
 ≥30 2.65 (2.41–2.91) 2.60 (2.35–2.87) 3.35 (2.79–4.03)
aValues are given as odds ratio (95% confidence interval).
b
Maternal age is also included as a confounder but is not shown because of the use of a quadratic term which is not easily interpretable.
cUnivariate associations.
dAdjusted for maternal age, parity, multiple pregnancy, and body mass index.
eAdjusted for maternal age, parity, multiple pregnancy, and body mass index. Outcome definition does not include a recorded systolic blood 
pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg.
fCalculated as weight in kilograms divided by the square of height in meters.
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Table 3
Logistic regression of factors associated with pregnancy-associated hypertension among women with HIV 
infection.a,b
Factor
Model adjusting for CD4 count among 
women with HIV infection (n=49 164)c
Model for timing of ART initiation 
among women taking ART (n=9918)d
HIV status and treatment
 Positive, untreated or given prophylaxis only 1 NA
 Positive, given ART 1.27 (1.04–1.55) NA
Parity ≥1 0.72 (0.59–0.87) 1.20 (0.79–1.83)
Multiple pregnancy 2.79 (1.84–4.24) 2.99 (1.35–6.62)
Baseline body mass indexe
 <18.5 1.16 (0.66–2.05) 0.59 (0.14–2.45)
 18.5–24 1 1
 25–29 1.47 (1.19–1.82) 1.56 (1.02–2.40)
 ≥30 3.73 (2.89–4.81) 4.48 (2.69–7.47)
Most recent CD4 count, cells/mm3
 <200 0.97 (0.71–1.34) 1.19 (0.68–2.08)
 200–250 1.14 (0.90–1.43) 1.17 (0.74–1.84)
 350–500 1.02 (0.81–1.29) 0.69 (0.39–1.19)
 ≥500 1 1
Timing of ART initiation
 Before pregnancy NA 1
 During pregnancy NA 0.91 (0.47–1.76)
Abbreviations: ART, antiretroviral therapy; NA, not available.
aValues are given as odds ratio (95% confidence interval).
b
Maternal age is included in all models as a confounder but is not shown because of the use of a quadratic term which is not easily interpretable.
cAdjusted for all maternal age, parity, multiple pregnancy, body mass index, CD4 T lymphocyte count, and ART.
dAdjusted for all maternal age, parity, multiple pregnancy, BMI, and CD4 T lymphocyte count.
eCalculated as weight in kilograms divided by the square of height in meters.
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